Compare RPRX & COO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPRX | COO |
|---|---|---|
| Founded | 1996 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 16.5B |
| IPO Year | 2020 | 1994 |
| Metric | RPRX | COO |
|---|---|---|
| Price | $49.36 | $64.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $51.40 | ★ $90.18 |
| AVG Volume (30 Days) | ★ 2.5M | 1.7M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.78 | 0.66 |
| Revenue | $2,378,193,000.00 | ★ $2,532,800,000.00 |
| Revenue This Year | $38.63 | $6.66 |
| Revenue Next Year | $4.73 | $5.18 |
| P/E Ratio | ★ $27.85 | $98.31 |
| Revenue Growth | 5.06 | ★ 18.41 |
| 52 Week Low | $31.97 | $61.78 |
| 52 Week High | $50.08 | $89.83 |
| Indicator | RPRX | COO |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 24.49 |
| Support Level | $35.34 | $64.19 |
| Resistance Level | N/A | $70.01 |
| Average True Range (ATR) | 0.88 | 1.64 |
| MACD | 0.03 | -0.38 |
| Stochastic Oscillator | 77.82 | 7.07 |
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.